Mitch Raponi

8.9k total citations
64 papers, 2.2k citations indexed

About

Mitch Raponi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mitch Raponi has authored 64 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 24 papers in Molecular Biology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mitch Raponi's work include PARP inhibition in cancer therapy (23 papers), Cancer Genomics and Diagnostics (19 papers) and Lung Cancer Treatments and Mutations (18 papers). Mitch Raponi is often cited by papers focused on PARP inhibition in cancer therapy (23 papers), Cancer Genomics and Diagnostics (19 papers) and Lung Cancer Treatments and Mutations (18 papers). Mitch Raponi collaborates with scholars based in United States, France and Australia. Mitch Raponi's co-authors include David G. Beer, Guoan Chen, Lesley Dossey, Hongtao Fan, Xiaoying Wu, Tim Jatkoe, Grace Lee, Greg M. Arndt, Hans Winkler and Nicholas C. Dracopoli and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

Mitch Raponi

63 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitch Raponi United States	19	1.6k	1.0k	609	402	149	64	2.2k
Audrey Petitjean France	9	1.3k 0.9×	704 0.7×	1.3k 2.2×	272 0.7×	195 1.3×	16	2.2k
Amir Moghaddam United Kingdom	17	1.6k 1.0×	943 0.9×	1.2k 2.0×	218 0.5×	90 0.6×	20	2.5k
Peter M. Haverty United States	29	2.4k 1.5×	677 0.6×	846 1.4×	351 0.9×	389 2.6×	38	3.3k
Zhongwu Lai United States	21	1.5k 0.9×	926 0.9×	1.4k 2.3×	1.2k 3.0×	304 2.0×	55	2.8k
Silje Nord Norway	21	1.1k 0.7×	917 0.9×	566 0.9×	233 0.6×	416 2.8×	40	1.9k
Nancy G. Azizian United States	8	1.5k 1.0×	580 0.6×	772 1.3×	361 0.9×	128 0.9×	8	2.1k
James Watters United States	21	1.2k 0.8×	400 0.4×	815 1.3×	326 0.8×	237 1.6×	40	1.9k
Sylvie Gazzéri France	36	2.5k 1.6×	677 0.6×	1.6k 2.6×	581 1.4×	157 1.1×	63	3.5k
Claude Allasia France	26	875 0.6×	527 0.5×	718 1.2×	180 0.4×	122 0.8×	58	1.9k
Birgitte Smith‐Sørensen Norway	17	1.4k 0.9×	674 0.6×	1.4k 2.4×	299 0.7×	289 1.9×	25	2.4k

Countries citing papers authored by Mitch Raponi

Since Specialization

Citations

This map shows the geographic impact of Mitch Raponi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitch Raponi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitch Raponi more than expected).

Fields of papers citing papers by Mitch Raponi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitch Raponi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitch Raponi. The network helps show where Mitch Raponi may publish in the future.

Co-authorship network of co-authors of Mitch Raponi

This figure shows the co-authorship network connecting the top 25 collaborators of Mitch Raponi. A scholar is included among the top collaborators of Mitch Raponi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitch Raponi. Mitch Raponi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paradkar, Sateja, Joseph Edmonds, Sam Friedman, et al.. (2024). NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ Depletion. Molecular Cancer Research. 22(10). 973–988. 1 indexed citations

Castellanos-Rizaldos, Elena, Dominik G. Grimm, Vasisht Tadigotla, et al.. (2018). Exosome-Based Detection of EGFR T790M in Plasma from Non–Small Cell Lung Cancer Patients. Clinical Cancer Research. 24(12). 2944–2950. 171 indexed citations

Zhao, Xin, Swati Kaushik, Kevin Lin, et al.. (2018). A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Reports. 23(3). 918–929. 30 indexed citations

Krug, Anne K., Daniel Enderle, Chris Karlovich, et al.. (2017). Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma. Annals of Oncology. 29(3). 700–706. 208 indexed citations

Wakelee, Heather A., Jonathan W. Goldman, Shirish M. Gadgeel, et al.. (2016). PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC. Journal of Thoracic Oncology. 11(11). S311–S312. 1 indexed citations

Smyth, Elizabeth, Andrea Loehr, Thomas Harding, et al.. (2016). Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial. Annals of Oncology. 27. vi220–vi220. 2 indexed citations

Piskorz, Anna, Kevin Lin, Elaina Mann, et al.. (2016). Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.. Journal of Clinical Oncology. 34(15_suppl). 5549–5549. 13 indexed citations

Ormanns, Steffen, Volker Heinemann, Mitch Raponi, et al.. (2014). Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. European Journal of Cancer. 50(11). 1891–1899. 29 indexed citations

Raponi, Mitch, Lesley Dossey, Tim Jatkoe, et al.. (2009). MicroRNA Classifiers for Predicting Prognosis of Squamous Cell Lung Cancer. Cancer Research. 69(14). 5776–5783. 333 indexed citations

10.

Arndt, Greg M., Lesley Dossey, Lara M. Cullen, et al.. (2009). Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 9(1). 374–374. 226 indexed citations

11.

Rolland, Delphine, Vincent Ribrag, Corinne Haïoun, et al.. (2009). Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial. Cancer Chemotherapy and Pharmacology. 65(4). 781–790. 15 indexed citations

12.

Raponi, Mitch & Jean‐Luc Harousseau. (2008). Development of genomic markers that predict response to molecularly targeted antileukemic therapy. Expert Opinion on Medical Diagnostics. 2(4). 361–372. 1 indexed citations

13.

Raponi, Mitch, Jean‐Luc Harousseau, Jeffrey E. Lancet, et al.. (2007). Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia. Clinical Cancer Research. 13(7). 2254–2260. 52 indexed citations

14.

Raponi, Mitch, Yi Zhang, Jack X. Yu, et al.. (2006). Gene Expression Signatures for Predicting Prognosis of Squamous Cell and Adenocarcinomas of the Lung. Cancer Research. 66(15). 7466–7472. 319 indexed citations

15.

Macpherson, Janet L., Maureen Boyd, Alison V. Todd, et al.. (2005). Long‐term survival and concomitant gene expression of ribozyme‐transduced CD4+ T‐lymphocytes in HIV‐infected patients. The Journal of Gene Medicine. 7(5). 552–564. 75 indexed citations

16.

Tran, Nham, Mitch Raponi, Ian W. Dawes, & Greg M. Arndt. (2004). Control of specific gene expression in mammalian cells by co‐expression of long complementary RNAs. FEBS Letters. 573(1-3). 127–134. 15 indexed citations

17.

Raponi, Mitch, R. T. Belly, Judith E. Karp, et al.. (2004). Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia. BMC Cancer. 4(1). 56–56. 70 indexed citations

18.

Raponi, Mitch. (2003). Double-stranded RNA-mediated gene silencing in fission yeast. Nucleic Acids Research. 31(15). 4481–4489. 35 indexed citations

19.

Backer, Marianne D. De, Mitch Raponi, & Greg M. Arndt. (2002). RNA-mediated gene silencing in non-pathogenic and pathogenic fungi. Current Opinion in Microbiology. 5(3). 323–329. 23 indexed citations

20.

Raponi, Mitch, David Atkins, Ian W. Dawes, & Greg M. Arndt. (2000). The Influence of Antisense Gene Location on Target Gene Suppression in the Fission Yeast Schizosaccharomyces pombe. Antisense and Nucleic Acid Drug Development. 10(1). 29–34. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact